List view / Grid view
6 July 2016 | By Victoria White, Digital Content Producer
The first subject has been dosed with immuno-oncology candidate HTL1071 in a Phase I clinical study, triggering a US$10 million payment to Heptares...
10 February 2016 | By Victoria White
HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia...
17 June 2015 | By Victoria White
Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, has announced the positive outcome of its Phase 1a study with HTL9936...
